Skip to content

Efficacy and Safety of Helicobacter Project Will

Efficacy and Safety of Helicobacter Project Will on treatment of Helicobacter pylori carriers; A 8 week, multi-center, Randomized, Double-blind, Placebo-Controlled Clinical Trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CRIS
Registry ID
KCT0002707
Enrollment
140
Registered
2018-02-23
Start date
2017-05-04
Completion date
Unknown
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : Helicobacter Project Will including Lactobacillus paracasei HP7 and extract from liquorice, once daily, post prandial 1 bottle (150ml/bottle), per oral, for 8 weeks

Sponsors

Kyung Hee University Hosipital at Gangdong
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Male and Female adult aged 19 - 70 years (2) Adult was diagnosed with H. pylori (+) in recent one year and did not have H. pylori eradication (3) Infomed consent form

Exclusion criteria

Exclusion criteria: 1) had a prescription for medications including PPI (Proton Pump Inhibitor)/Histamin-2 blocker, antibiotics for example clarithromycin, amoxicillin, metronidazole or tetracycline, mucosal protector such as bismuth steroid, NSAID, probiotics less than 2 weeks before the screening visit; 2) consumed dietary supplements potentially interfering with this trial (such as probiotics, prebiotics, or fiber); 3) exhibited alarm signs (e.g., abnormal weight loss, hematochezia, anemia, or significant bowel habit changes); 4) had neurological or psychiatric disorders; 5) were pregnant or breastfeeding; 6) were drug users or alcoholics; 7) had undergone a previous colorectal operation; and 8) had significant laboratory abnormalities

Design outcomes

Primary

MeasureTime frame
Interval change in 13 C-Urea Breath Test

Secondary

MeasureTime frame
Positive rate of H. pylori measued by 13 C-Urea Breath Test;Positive rate of H. pylori measued by Campylobacter-like organism test;infection degree of H. pylori measued by Sydney system through tissue biopsy;Interval change in fecal microbiome;GI symptoms measured by Gastrointestinal Symptom Rating Scale;questionnaire about Gastrointestinal symptoms;Quality of Life measured by WHOQOL-BREF (World Health Organization Quality of Life Assessment Instrument

Countries

Korea, Republic of

Contacts

Public ContactJin Young Yoon

Kyung Hee University Hosipital at Gangdong

htherehthere@gmail.com+82-2-440-6095

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026